Evaluation of Standard-of-care Intravitreal Aflibercept Treatment Practices in Patients with Diabetic Macular Oedema in the UK: DRAKO Study Outcomes

Overview

Journal Eye (Lond)

Specialty Ophthalmology

Date 2023 Jan 18

PMID 36653595

Authors

Sobha Sivaprasad

Faruque Ghanchi

Simon P Kelly

Ajay Kotagiri

James Talks

Peter Scanlon

Hellen McGoey

Andrew Nolan

Moneeb Saddiq

Jackie Napier

Peter Morgan-Warren

Affiliations

Soon will be listed here.

Abstract

Background/objectives: DRAKO (NCT02850263) was a 24-month, prospective, non-interventional, multi-centre cohort study enrolling patients with diabetic macular oedema (DMO) including central involvement. The study evaluated UK standard-of-care intravitreal aflibercept (IVT-AFL) treatment. This analysis describes the treatment pathway and service provision for the anti-vascular endothelial growth factor (VEGF) treatment-naïve (C1) and non-naïve patients (C2) who received prior anti-VEGF treatment for DMO other than IVT-AFL.

Methods: Mean changes in best-corrected visual acuity and central subfield thickness were measured and stratified by baseline factors, including ethnicity and administration of five initial monthly injections within predefined windows. Clinic visits were classified as treatment only (T1), monitoring assessment only (T2), combined visits (T3) or post-injection visits with no treatment or assessment (T4).

Results: Median time from decision to treat to treatment was 6 days. As a percentage of total visits, T1, T2, T3 and T4 were 7%, 42%, 48% and 3% for C1 and 11%, 39%, 48% and 2% for C2. Most IVT-AFL injections were administered by healthcare professionals (HCPs) other than doctors (C1, 57.4%; C2, 58.5%). The percentage of treatments associated with a procedure-related adverse event where at least 75% of injections were completed by the same injector role were similar for doctors and other HCPs (C1, 1.1% and 0.8%; C2, 0.7%, and 1.0%).

Conclusions: Results indicate that upon DMO diagnosis, patients were treated promptly, and most visits were combined (treatment and assessment) or monitoring only. Most IVT-AFL was administered by non-physicians with a similar treatment-related safety profile as IVT-AFL administered by physicians.

References

Varma R, Bressler N, Doan Q, Gleeson M, Danese M, Bower J . Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol. 2014; 132(11):1334-40. PMC: 4576994. DOI: 10.1001/jamaophthalmol.2014.2854. View

Moss S, Klein R, Klein B . The 14-year incidence of visual loss in a diabetic population. Ophthalmology. 1998; 105(6):998-1003. DOI: 10.1016/S0161-6420(98)96025-0. View

Hex N, Bartlett C, Wright D, Taylor M, Varley D . Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012; 29(7):855-62. DOI: 10.1111/j.1464-5491.2012.03698.x. View

Rasul A, Subhi Y, Sorensen T, Munch I . Non-physician delivered intravitreal injection service is feasible and safe - a systematic review. Dan Med J. 2016; 63(5). View

Stefansson E, Bek T, Porta M, Larsen N, Kristinsson J, Agardh E . Screening and prevention of diabetic blindness. Acta Ophthalmol Scand. 2000; 78(4):374-85. DOI: 10.1034/j.1600-0420.2000.078004374.x. View

Klein R, Klein B, Moss S, Davis M, DeMets D . The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol. 1984; 102(4):527-32. DOI: 10.1001/archopht.1984.01040030405011. View

Nguyen Q, Brown D, Marcus D, Boyer D, Patel S, Feiner L . Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology. 2012; 119(4):789-801. DOI: 10.1016/j.ophtha.2011.12.039. View

DaCosta J, Hamilton R, Nago J, Mapani A, Kennedy E, Luckett T . Implementation of a nurse-delivered intravitreal injection service. Eye (Lond). 2014; 28(6):734-40. PMC: 4058629. DOI: 10.1038/eye.2014.69. View

Simcock P, Kingett B, Mann N, Reddy V, Park J . A safety audit of the first 10 000 intravitreal ranibizumab injections performed by nurse practitioners. Eye (Lond). 2014; 28(10):1161-4. PMC: 4194327. DOI: 10.1038/eye.2014.153. View

10.

Sivaprasad S, Ghanchi F, Kelly S, Kotagiri A, Talks J, Scanlon P . Evaluation of standard of care intravitreal aflibercept treatment of diabetic macular oedema treatment-naive patients in the UK: DRAKO study 12-month outcomes. Eye (Lond). 2021; 36(1):64-71. PMC: 8727562. DOI: 10.1038/s41433-021-01624-9. View

11.

Martin-Merino E, Fortuny J, Rivero-Ferrer E, Lind M, Garcia-Rodriguez L . Risk factors for diabetic macular oedema in type 2 diabetes: A case-control study in a United Kingdom primary care setting. Prim Care Diabetes. 2017; 11(3):288-296. DOI: 10.1016/j.pcd.2017.03.002. View

12.

Sivaprasad S, Gupta B, Gulliford M, Dodhia H, Mohamed M, Nagi D . Ethnic variations in the prevalence of diabetic retinopathy in people with diabetes attending screening in the United Kingdom (DRIVE UK). PLoS One. 2012; 7(3):e32182. PMC: 3297598. DOI: 10.1371/journal.pone.0032182. View

13.

Fong D, Aiello L, Ferris 3rd F, Klein R . Diabetic retinopathy. Diabetes Care. 2004; 27(10):2540-53. DOI: 10.2337/diacare.27.10.2540. View

14.

Michelotti M, Abugreen S, Kelly S, Morarji J, Myerscough D, Boddie T . Transformational change: nurses substituting for ophthalmologists for intravitreal injections - a quality-improvement report. Clin Ophthalmol. 2014; 8:755-61. PMC: 3998867. DOI: 10.2147/OPTH.S59982. View

15.

Cohen S, Gardner T . Diabetic Retinopathy and Diabetic Macular Edema. Dev Ophthalmol. 2015; 55:137-46. PMC: 4775164. DOI: 10.1159/000438970. View

16.

Brand C . Management of retinal vascular diseases: a patient-centric approach. Eye (Lond). 2012; 26 Suppl 2:S1-16. PMC: 3335302. DOI: 10.1038/eye.2012.32. View

17.

Amoaku W, Ghanchi F, Bailey C, Banerjee S, Banerjee S, Downey L . Diabetic retinopathy and diabetic macular oedema pathways and management: UK Consensus Working Group. Eye (Lond). 2020; 34(Suppl 1):1-51. PMC: 7337227. DOI: 10.1038/s41433-020-0961-6. View

18.

Brown D, Schmidt-Erfurth U, Do D, Holz F, Boyer D, Midena E . Intravitreal Aflibercept for Diabetic Macular Edema: 100-Week Results From the VISTA and VIVID Studies. Ophthalmology. 2015; 122(10):2044-52. DOI: 10.1016/j.ophtha.2015.06.017. View